With Fibrogen Inc. and U.S. partner Astrazeneca plc, of London, set to roll out data in the fourth quarter on roxadustat (roxa) for anemia associated with chronic kidney disease (CKD) – and with a filing for approval possible in the first half of next year – speculation has begun about the oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor's odds for success.